Abstract:Objective To investigate the correlation of multidrug resistance gene 1 (MDR1),NR3C1 gene polymorphisms and clinical risk factors with efficacy,dependence,and resistance of glucocorticoid (GC) in patients with inflammatory bowel disease (IBD).Methods Anti coagulation blood samples of 196 healthy controls and 105 IBD patients received GC therapy were collected.There were 62 ulcerative colitis (UC) and 43 Crohn's disease (CD) in the IBD patients.The number of GC sensitive,GC dependent and GC resistant of UC patients were 36,13 and 13,respectively,and those of CD patients were 24,11 and eight.GC refractoriness included GC dependence and resistance.The genotype of MDR1 C3435T and NR3C1 Bcl Ⅰ of all the subjects was detected by the restriction fragment length polymorphism-polymerase chain reaction (RFLP-PCR).The correlation between each genotype frequency,clinical features of patients with IBD and the efficacy of GC treatment was analyzed by Chisquare test,Fisher exact probability method or t test.Results Among UC patients,the disease course of GC refractory group and GC resistant group was longer than that of GC sensitive group ((6.660±1.523)years,(6.500±1.111) yearsvs (3.350±0.697) years,t=2.211,P=0.031; t=2.930,P=0.005).The serum level of C reaction protein (CRP) of GC refractory group was higher than that of GC sensitive group ((47.628±13.913) mg/Lvs (16.854±4.121) mg/L,t=2.121,P=0.047).The chronic relapse type was more common in GC refractory UC patients (Fisher exact probability method,P=0.035),and severe patients were more common in UC with GC resistance (Fisher exact probability method,P=0.021).The white blood cell count of GC resistant and GC refractory CD patient was lower than that of GC sensitive CD patients ((5.710 ± 0.604) ×109/L,(5.878±0.405) × 109/L vs (7.814 ±0.670) × 109/L,t=2.334,P=0.028; t=2.045,P=0.018).Patients with extraqntestinal manifestations was more common in CD with GC resistance (Fisher exact probability method,P=0.035).There was no statistically significant difference in the frequencies of MDR1 C3435T,NR3C1 Bcl Ⅰ genotypes,allelic genes and gene carrier among control group and GC sensitive dependent and resistant group of IBD patients.However,the frequency of MDR1 C3435T gene carrier was significantly different between GC sensitive group and GC refractory group,especially between GC sensitive group and GC resistance group (68.33％ vs 48.89％,x2 =4.051,P=0.044; 68.33％ vs 42.86％,x2 =4.274,P =0.039).Conclusions GC sensitivity of IBD patients with MDR1 C3435T loci T gene carrier was higher than that of IBD patients without T gene carrier.NR3C1 gene polymorphisms was not related with GC resistance and GC dependence.Compared with GC sensitive IBD patients,in GC resistant and GC dependent IBD pantient UC patients with long disease course,chronic relapse type,severe type,high level of CRP and CD patients with low white blood cell count and extra-intestinal manifestations were more common.

Interleukin-1β As a Predictor of Glucocorticoid Response in Ulcerative Colitis

Significance of Glucocorticoid Receptor Expression in Colonic Mucosal Cells of Patients with Ulcerative Colitis

Differential Expression of Serum Micrornas in Glucocorticoid-Resistant Patients with Ulcerative Colitis.

[Study on Glucocorticoid Receptor Alpha and Beta in Colonic Mucosal Cell of Patients with Ulcerative Colitis].

Corticosteroid Therapy in Ulcerative Colitis: Clinical Response and Predictors.

IDDF2019-ABS-0186 Correlation Between Serological Biomarkers and Disease Activity in Patients with Inflammatory Bowel Disease

Identified Potential Biomarkers May Predict Primary Nonresponse to Infliximab in Patients with Ulcerative Colitis.

P021 Higher TNFα and IL-6 mucosal levels in ulcerative colitis patients with more severe endoscopic activity

P138 Novel serum markers for predicting disease activity in ulcerative colitis: results from a retrospective case-control study

Clinical Significance and Assessment of Cytokines in Various Stages of Ulcerative Colitis

Biomarkers for Monitoring of Changes in Disease Activity in Ulcerative Colitis

BIOACTIVE INTERLEUKIN-1 DETECTED IN IBD PATIENT INTESTINAL BIOPSIES IS A HALLMARK OF ULCERS AND CORRELATES WITH TRANSCRIPTOMIC ASSESSMENTS, INCLUDING AN ULCER-ASSOCIATED GENE MODULE

Calcitonin Gene-Related Peptide Is a Promising Marker in Ulcerative Colitis

Correlation of Multidrug Resistance Genes and Clinical Risk Factors with Glucocorticoid Response in Patients with Inflammatory Bowel Disease

P527 Leucine-rich alpha 2 glycoprotein- A useful biomarker to discriminate mucosal healing in CRP-negative ulcerative colitis

Expression and Clinical Significance of IL-17 and IL-17 Receptor in Ulcerative Colitis.

Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis

Mucosal cytokine expression associated with deep endoscopic mucosal healing in ulcerative colitis

Evaluating the significance of ECSCR in the diagnosis of ulcerative colitis and drug efficacy assessment

P869 Deep ulcers in acute Ulcerative Colitis at index endoscopy predict corticosteroid resistance

Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis